244 related articles for article (PubMed ID: 28922567)
1. Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
Mansour MSI; Seidal T; Mager U; Baigi A; Dobra K; Dejmek A
Cancer Cytopathol; 2017 Dec; 125(12):908-917. PubMed ID: 28922567
[TBL] [Abstract][Full Text] [Related]
2. Higher concordance of PD-L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma.
Mansour MSI; Seidal T; Mager U; Dobra K; Brunnström H; Dejmek A
Cancer Cytopathol; 2021 Jun; 129(6):468-478. PubMed ID: 33493383
[TBL] [Abstract][Full Text] [Related]
3. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
4. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
[TBL] [Abstract][Full Text] [Related]
5. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
Sobhani N; Roviello G; Pivetta T; Ianza A; Bonazza D; Zanconati F; Giudici F; Bottin C; Corona SP; Guglielmi A; Rizzardi C; Milione M; Cortale M; Confalonieri M; Generali D
Mol Biol Rep; 2019 Jun; 46(3):2713-2720. PubMed ID: 30840203
[TBL] [Abstract][Full Text] [Related]
6. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
7. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
Zou Y; Xu L; Tang Q; You Q; Wang X; Ding W; Zhao J; Ren G
BMC Cancer; 2020 Apr; 20(1):344. PubMed ID: 32321471
[TBL] [Abstract][Full Text] [Related]
8. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
Cedrés S; Ponce-Aix S; Zugazagoitia J; Sansano I; Enguita A; Navarro-Mendivil A; Martinez-Marti A; Martinez P; Felip E
PLoS One; 2015; 10(3):e0121071. PubMed ID: 25774992
[TBL] [Abstract][Full Text] [Related]
9. Aquaporin-1 expression in fluoro-edenite-induced mesothelioma effusions: An approach by cell-block procedure.
Angelico G; Ieni A; Caltabiano R; Zeppa P; Tuccari G
Cytopathology; 2018 Oct; 29(5):455-460. PubMed ID: 29873855
[TBL] [Abstract][Full Text] [Related]
10. Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
Cedrés S; Ponce-Aix S; Pardo-Aranda N; Navarro-Mendivil A; Martinez-Marti A; Zugazagoitia J; Sansano I; Montoro MA; Enguita A; Felip E
Lung Cancer; 2016 Jun; 96():1-6. PubMed ID: 27133741
[TBL] [Abstract][Full Text] [Related]
11. Investigation of pd-l1 (cd274), pd-l2 (pdcd1lg2), and ctla-4 expressions in malignant pleural mesothelioma by immunohistochemistry and real-time polymerase chain reaction methods.
Sule Kutlar Dursun F; Alabalik U
Pol J Pathol; 2022; 73(2):111-119. PubMed ID: 36172747
[TBL] [Abstract][Full Text] [Related]
12. Malignant Mesothelioma Effusions Are Infiltrated by CD3
Khanna S; Thomas A; Abate-Daga D; Zhang J; Morrow B; Steinberg SM; Orlandi A; Ferroni P; Schlom J; Guadagni F; Hassan R
J Thorac Oncol; 2016 Nov; 11(11):1993-2005. PubMed ID: 27544053
[TBL] [Abstract][Full Text] [Related]
13. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
[TBL] [Abstract][Full Text] [Related]
14. Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas.
Jain D; Sukumar S; Mohan A; Iyer VK
Cytopathology; 2018 Dec; 29(6):550-557. PubMed ID: 29938855
[TBL] [Abstract][Full Text] [Related]
15. A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens.
Bubendorf L; Conde E; Cappuzzo F; Langfort R; Schildhaus HU; Votruba J; Concha-López Á; Esteban-Rodriguez I; Feng J; Devenport J; Boyiddle C; Morris S; Trunzer K; Kerr KM
Cancer Cytopathol; 2020 Dec; 128(12):928-938. PubMed ID: 32721105
[TBL] [Abstract][Full Text] [Related]
16. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
[TBL] [Abstract][Full Text] [Related]
17. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
Nguyen BH; Montgomery R; Fadia M; Wang J; Ali S
Asia Pac J Clin Oncol; 2018 Feb; 14(1):69-73. PubMed ID: 29105302
[TBL] [Abstract][Full Text] [Related]
19. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
Kao SC; Cheng YY; Williams M; Kirschner MB; Madore J; Lum T; Sarun KH; Linton A; McCaughan B; Klebe S; van Zandwijk N; Scolyer RA; Boyer MJ; Cooper WA; Reid G
J Thorac Oncol; 2017 Sep; 12(9):1421-1433. PubMed ID: 28629895
[TBL] [Abstract][Full Text] [Related]
20. Expression status of PD-L1 and B7-H3 in mesothelioma.
Matsumura E; Kajino K; Abe M; Ohtsuji N; Saeki H; Hlaing MT; Hino O
Pathol Int; 2020 Dec; 70(12):999-1008. PubMed ID: 33027549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]